Association between anti-PGL-I IgM and clinical and demographic parameters in leprosy

Leprosy Review

Volumn 77, Issue 4, 2006, Pages 343-355

  Schuring, Ron P ^a   Moet, F Johannes ^b   Pahan, David ^c   Richardus, Jan Hendrik ^b   Oskam, Linda ^a  

^a ROYAL TROPICAL INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Danish Bangladesh Leprosy Mission   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN M; PHENOLIC GLYCOLIPID 1 ANTIBODY; PHENOLIC GLYCOLIPID I; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; BACTERIUM DETECTION; BCG VACCINATION; CORRELATION ANALYSIS; DATA ANALYSIS; DEMOGRAPHY; DISEASE CLASSIFICATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LEPROSY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM LEPRAE; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SKIN INFECTION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BANGLADESH; CHILD; CHILD, PRESCHOOL; FEMALE; GLYCOLIPIDS; HUMANS; IMMUNOGLOBULIN M; LEPROSY; MALE; MIDDLE AGED; MYCOBACTERIUM LEPRAE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SKIN;

EID: 33947253226     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. World Health Organization. Leprosy - global situation 2004.[Online.] http://www.who.int/lep/stat2002/global02.htm.
2. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis, 1966; 34: 255-273.
3. WHO Expert Committee on Leprosy. Seventh Report. Geneva, 1998. WHO Technical Report Series, No. 874. World Health Organization.
4. Kumarasinghe SPW, Kumarasinghe MP. Correspondence: should large lesions of leprosy be considered as "multibacillary" for treatment purposes even if the total number of lesions is less than five? Int J Lepr Other Mycobact Dis, 2003; 72: 173-174.
5. Ridley DS. Therapeutic trials in leprosy using serial biopsies. Lepr Rev, 1958; 29: 45-52.
6. Bührer-Sékula S, Smits HL, Gussenhoven GC et al. Simple and fast lateral flow test for classification of leprosy patients and identification of contacts with high risk of developing leprosy. J Clin Microbiol, 2003; 41: 1991-1995.
7. Bührer-Sékula S, Sarno EN, Oskam L et al. Use of ML dipstick as a tool to classify leprosy patients. Int J Lepr Other Mycobact Dis, 2000; 68: 456-463.
8. Moet FJ, Oskam L, Faber R, Pahan D, Richardus JH. A study on transmission and a trail of chemoprophylaxis in contacts of leprosy patients: design, methodology and recruitment findings of COLEP. Lepr Rev, 2004; 75: 376-388.
9. Danish Bangladesh Leprosy Mission. Annual Report, 2001.
10. Brett SJ, Payne SN, Gigg J et al. Use of synthetic glycoconjugates containing the M. leprae specific and immunodominant epitope of phenolic glycolipid I in the serology of leprosy. Clin Exp Immunol, 1986; 64: 476-483.
11. Fujiwara T, Hunter SW, Cho SN et al. Chemical synthesis and serology of disaccharides and trisaccharides of phenolic glycolipid antigens from the leprosy bacillus and preparation of a disaccharide protein conjugate for serodiagnosis of leprosy. Infect Immun, 1984; 43: 245-252.
12. Pattyn SR. Minimal requirements for the laboratory diagnosis of leprosy in field conditions. Acta Leprol, 1983; 1: 33-40.
13. Van Brakel WH, de Soldenhoff R, McDougall AC. The allocation of leprosy patients into paucibacillary and multibacillary groups for multidrug therapy, taking into account the number of body areas affected by skin, or skin and nerve lesions. Lepr Rev, 1992; 63: 231-246.
14. World Health Organization. Leprosy disabilities: magnitude of the problem. Wkly Epidemiol Rec, 1995; 70: 269-276.
15. Oskam L, Slim E, Bührer-Sékula S. Serology: recent developments, strengths, limitations and prospects: a state of the art overview. Lepr Rev, 2003; 74: 196-205.
16. Tomimori-Yamashita J, Nguyen TH, Maeda SM et al. Anti-phenolic glycolipid-I (PGL-I) determination using blood collection on filter paper in leprosy patients. Rev Inst Med Trop Sao Paulo, 1999; 41: 239-242.
17. Danish Bangladesh Leprosy Mission. Annual Report, 2003.
18. Withington SG, Joha S, Baird D et al. Assessing socio-economic factors in relation to stigmatization, impairment status, and selection for socio-economic rehabilitation: a 1-year cohort of new leprosy cases in north Bangladesh. Lepr Rev, 2003; 74: 120-132.
19. Fine PE, Ponnighaus JM, Burgess P et al. Seroepidemiological studies of leprosy in northern Malawi based on an enzyme-linked immunosorbent assay using synthetic glycoconjugate antigen. Int J Lepr Other. Mycobact Dis, 1988; 56: 243-254.
20. Roche PW, Britton WJ, Failbus SS et al. Operational value of serological measurements in multibacillary leprosy patients clinical and bacteriological correlates of antibody responses. Int J Lepr Other Mycobact Dis, 1990; 58: 480-490.
21. Chaudhury S, Hazra SK, Saha B et al. September An eight-year field trial on antileprosy vaccines among high-risk household contacts in the Calcutta metropolis. Int J Lepr Other Mycobact Dis, 1994; 62: 389-394.
22. Fine PE. BCG vaccination against tuberculosis and leprosy. Br Med Bull, 1988; 44: 691-703.
23. Cho SN, Yanagihara DL, Hunter SW et al. Serological specificity of phenolic glycolipid I from Mycobacterium leprae and use in serodiagnosis of leprosy. Infect Immun, 1983; 41: 1077-1083.
24. Levis WR, Meeker HC, Schuller-Levis G et al. IgM and IgG antibodies to phenolic glycolipid I from Mycobacterium leprae in leprosy: insight into patient monitoring, erythema nodosum leprosum, and bacillary persistence. J Invest Dermatol, 1986; 86: 529-534.
25. Van Beers SM, Izumi S, Madjid B et al. An epidemiological study of leprosy infection by serology and polymerase chain reaction. Int J Lepr, 1994; 62: 1-9.
26. Foss NT, Callera F, Alberto FL. Anti-PGL1 levels in leprosy patients and their contacts. Brazil J Med Biol Res, 1993; 26: 43-51.
27. Krishnamurthy P, Rao PS, Reddy BN et al. September. Seroepidemiological study of leprosy in a highly endemic population of south India based on an ELISA using synthetic PGL-I. Int J Lepr Other Mycobact Dis, 1991; 59: 426-431.
28. Maddison SE, Stewart CC, Farshy CE, Reimer CB. The relationship of race, sex, and age to concentrations of serum immunoglobulins expressed in international units in healthy adults in the USA. Bull World Health Org, 1975; 52: 179-185.
29. Richardus JH, Meima A, Croft RP, Habbema JD. Case detection, gender and disability in leprosy in Bangladesh: a trend analysis. Lepr Rev, 1999; 70: 160-173.
30. Bakker MI, Hatta M, Kwenang A et al. Population survey to determine risk factors for Mycobacterium leprae transmission and infection. Int J Epidemiol, 2004; 33: 1329-1336.
31. Bakker MI, Hatta M, Kwenang A et al. Risk factors for developing leprosy - a population- based cohort study in Indonesia. Lepr Rev, 2006; 77: 48-61.
32. Douglas JT, Cellona RV, Fajardo TT, Jr et al. Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. Clin Diagn Lab Immunol, 2004; 11: 897-900.
33. Fine PE, Sterne JA, Ponnighaus JM et al. Household and dwelling contact as risk factors for leprosy in northern Malawi. Am J Epidemiol, 1997; 146: 91-102.